Skip to main navigation

Investor Relations

Home
Overview
News & Events
Stock Information
Financials
- SEC Filings
- Quarterly Results
Governance
Meet F-Star
Publications
IR Resources
- Investor Contact
- Email Alerts

Press Releases

Year

Dec 07, 2021

F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021

PDF Version

Nov 29, 2021

F-star Therapeutics to Host Virtual R&D Day on December 6, 2021

PDF Version

Nov 12, 2021

F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference

PDF Version

Nov 10, 2021

F-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

PDF Version

Nov 01, 2021

F-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021

PDF Version

Oct 20, 2021

F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics

PDF Version

Sep 16, 2021

F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021

PDF Version

Sep 09, 2021

F-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

PDF Version

Aug 12, 2021

F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

PDF Version

Aug 10, 2021

F-star Therapeutics is Granted Composition of Matter Patent for its Novel Second Generation STING Agonist, SB 11285

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page

Shareholder Tools

Print Page
RSS
Contact IR

Request Email Alerts

© 2021 F-star Therapeutics, Inc.

Footer Legal

Disclaimer
Privacy Policy
Cookie Policy
Careers
Contact Us
Sitemap

Footer Social

Get in touch